Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trialAmanda Huff, Neeha Zaidi, Maureen Berg et al.|Nature Communications|2026Cited by 15
Abstract CT264: Mutant KRAS peptide vaccine combined with ipilimumab/nivolumab in advanced mismatch repair proficient/microsatellite stable (MMRp/MSS) colorectal cancer: Preliminary analysis from a phase I studyHejia Wang, Neeha Zaidi, Amanda L. Huff et al.|Cancer Research|2025Cited by 3
First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohortsSaurav D. Haldar, Neeha Zaidi, Amanda L. Huff et al.|Cancer Discovery|2026Cited by 1